 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12...56789101112131415...220221» |
- | LY294002 / Eli Lilly
Journal: Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. (Pubmed Central) - Dec 4, 2023
Increased intestinal urate excretion resulted in spontaneous SUA downregulation during acute gout attacks. Inflammation-induced PI3K/Akt activation and ABCG2 expression in epithelial cells might contribute to the upregulation of intestinal uric acid excretion.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Journal: CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase ? (CD26). (Pubmed Central) - Dec 4, 2023
These findings underscore the novel role of CXCR2 in the regulation of not only ponatinib-resistant CML cells, but also CML leukemic stem cells. Consequently, our study proposes that targeting CXCR2 holds promise as a viable therapeutic strategy for addressing patients with CML grappling with ponatinib resistance.
- | fenofibrate / Generic mfg.
Journal: Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling. (Pubmed Central) - Dec 3, 2023
Meanwhile, in vivo dosing of fenofibrate ameliorated the downregulated amplitudes of ERG c-wave in HFD-fed mice and suppressed the HFD-induced oxidative injury and inflammatory response in RPE tissues. Our results suggested that fenofibrate ameliorated RPE cell damage induced by excessive fat in vitro and in vivo, in part, through activation of the PI3K/AKT signaling pathway.
- | sorafenib / Generic mfg.
Journal: Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/?-catenin pathways in hepatocellular carcinoma. (Pubmed Central) - Dec 2, 2023
activity, suggesting a novel therapeutic strategy for HCC. Video Abstract.
- ||||||||| Aliqopa (copanlisib) / Bayer
Trial completion date, Trial termination, Combination therapy: CHRONOS-4: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (clinicaltrials.gov) - Dec 1, 2023
P3, N=547, Terminated, Sponsor: Bayer
The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.
- | Preclinical, Journal: Browning of Mammary Fat Suppresses Pubertal Mammary Gland Development of Mice via Elevation of Serum Phosphatidylcholine and Inhibition of PI3K/Akt Pathway. (Pubmed Central) - Nov 29, 2023
Furthermore, DOPC suppressed the activation of the PI3K/Akt pathway, while the DOPC-inhibited HC11 proliferation was reversed by SC79, an Akt activator, suggesting the involvement of the PI3K/Akt pathway in the DOPC-inhibited proliferation of HC11. Together, the browning of mammary fat suppressed the development of the pubertal mammary gland, which was associated with the elevated serum DOPC and the inhibition of the PI3K/Akt pathway.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment closed, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 29, 2023
P1/2, N=106, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Together, the browning of mammary fat suppressed the development of the pubertal mammary gland, which was associated with the elevated serum DOPC and the inhibition of the PI3K/Akt pathway. Suspended --> Active, not recruiting
- | progesterone / Generic mfg.
Journal: Attenuated AKT signaling by miR-146a-5p interferes with chicken granulosa cell proliferation, lipid deposition and progesterone biosynthesis. (Pubmed Central) - Nov 29, 2023
In summary, the findings revealed that miR-146a-5p suppressed cell growth, lipid deposition, and progesterone biosynthesis via the DEGS1/AKT pathway. These results may further enrich our understandings of how non-coding RNA regulates productive performance in chickens.
- | doxorubicin hydrochloride / Generic mfg.
Journal: USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/AKT pathway. (Pubmed Central) - Nov 29, 2023
This study demonstrates that USP10 could reduce DOX-induced resistance of TC cells to DOX therapy and could suppress TC malignant behavior by inhibiting the PI3K/AKT pathway. Furthermore, USP10 targeted ABCG2 to inhibit all these malignant processes, therefore, either increasing USP10 expression or inhibiting ABCG2 could be used as novel targets for treating DOX-resistant thyroid cancer.
- | MEN1611 / Menarini, Herceptin (trastuzumab) / Roche
Journal, Combination therapy, Metastases: Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients. (Pubmed Central) - Nov 29, 2023
A slightly lower exposure (i.e., 25% lower) was found for the 3-weekly s.c. schedule. This important outcome confirmed the adequacy of the therapeutic dose administered in the ongoing phase 1b B-PRECISE-01 study in patients with HER2+ PI3KCA mutated advanced/metastatic BC.
- | Journal: D-allose Inhibits TLR4/PI3K/AKT Signaling to Attenuate Neuroinflammation and Neuronal Apoptosis by Inhibiting Gal-3 Following Ischemic Stroke. (Pubmed Central) - Nov 29, 2023
This important outcome confirmed the adequacy of the therapeutic dose administered in the ongoing phase 1b B-PRECISE-01 study in patients with HER2+ PI3KCA mutated advanced/metastatic BC. In summary, D-allose plays a crucial role in inhibiting inflammation after IS by suppressing Gal-3/TLR4/PI3K/AKT signaling pathway in vitro and in vivo.
- | Journal, Real-world evidence, Real-world: Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era. (Pubmed Central) - Nov 28, 2023
This study reported similar clinical features of COVID-19 in our cohort with that of non-hematological malignancy (HM) patients, while the proportion of severe/critical COVID-19 and the mortality rate were relatively higher than non-HM patients. Our findings provided valuable experience to aid clinical researchers with managing lymphoma patients participating in registered clinical trials during the ongoing pandemic of the Omicron variant.
- | Journal: Klotho inhibits IGF1R/PI3K/AKT signalling pathway and protects the heart from oxidative stress during ischemia/reperfusion injury. (Pubmed Central) - Nov 27, 2023
Klotho reduced NADPH oxidase 2 (NOX2) (p?=?0.0390), ROS/RNS (p?=?0.0435) and HO (p?=?0.0392) levels, and heart damage (p?=?0.0286) in the hearts subjected to IRI. In conclusion, Klotho contributed to the protection of the heart against IRI and oxidative stress via inhibition of the IGF1R/PI3K/AKT pathway, thus can be recognized as a novel cardiopreventive/cardioprotective agent.
- | Journal: Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells. (Pubmed Central) - Nov 27, 2023
In conclusion, Klotho contributed to the protection of the heart against IRI and oxidative stress via inhibition of the IGF1R/PI3K/AKT pathway, thus can be recognized as a novel cardiopreventive/cardioprotective agent. In the pharmacokinetic study, the administration of 1
- | Journal: The myocardium utilizes a platelet-derived growth factor receptor alpha (Pdgfra) - phosphoinositide 3-kinase (PI3K) signaling cascade to steer towards the midline during zebrafish heart tube formation. (Pubmed Central) - Nov 27, 2023
Moreover, we find that PI3K activity is dependent on and interacts with Pdgfra to regulate myocardial movement. Together our findings reveal an intrinsic myocardial steering mechanism that responds to extrinsic cues during the initiation of cardiac development.
- | sirolimus / Generic mfg.
Journal: Curcumin inhibits the activity and induces apoptosis of activated hepatic stellate cell by suppressing autophagy. (Pubmed Central) - Nov 27, 2023
Our results showed that rapamycin, an autophagy activator, could partly offset the effects of curcumin on autophagy and apoptosis of LX-2 cells, while 3-Methyladenine (3-MA), an autophagy inhibitor, could enhance these effects...Overall, we demonstrated that curcumin could inhibit the activity and promote LX-2 cells apoptosis by suppressing autophagy by activating the PI3K/Akt/mTOR signal pathway. In addition, lipid recovery and energy deprivation due to autophagy inhibition may be the exact mechanism by which curcumin attenuates the pro-fibrotic activity of LX-2.
- | Journal, PD(L)-1 Biomarker, IO biomarker: BATF2 inhibits PD-L1 expression and regulates CD8T cells infiltration in non-small cell lung cancer. (Pubmed Central) - Nov 27, 2023
Based on bioinformatics analysis, we found the function of BATF2 in promoting anti-tumor immune response in patients with NSCLC, which is mediated by BATF2 enhances CD8 T cells infiltration as well as activation. BATF2 from circulating and tissue can serve as an efficient biomarker to predict diagnosis, prognosis and immunotherapy efficacy.
- | Journal: Protein interaction network analysis of mTOR signaling reveals modular organization. (Pubmed Central) - Nov 27, 2023
Using primary fibroblasts from individuals with overgrowth disorders caused by pathogenic PIK3CA or MTOR variants, we find that hyperactivation of mTOR pathway components is reflected in a hyperactive PIN. Our data define a "modular" organization of the mTOR PIN in which coordinated groups of interactions respond to activation or inhibition of distinct nodes, and demonstrate that kinase inhibitors affect the modular network architecture in a complex manner, inconsistent with simple linear models of signal transduction.
- | Journal, Myeloid-derived suppressor cells: Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways. (Pubmed Central) - Nov 27, 2023
The identification of PI3K-AKT and Wnt signal transduction pathways as respective inducers of the immunomodulatory capacity of M-MDSCs and TolDCs provides opportunities to overcome suppressive myeloid cells in cancer patients and optimize therapeutic application of TolDCs in patients with autoimmune diseases. Lastly, the observed similarities between generated- and patient-derived M-MDSCs support the use of in vitro generated M-MDSCs as powerful model to investigate the functionality of human MDSCs.
- | Journal: Traditional Medicine Pien Tze Huang Suppresses Colorectal Tumorigenesis through Restoring Gut Microbiota and Metabolites. (Pubmed Central) - Nov 27, 2023
Lastly, the observed similarities between generated- and patient-derived M-MDSCs support the use of in vitro generated M-MDSCs as powerful model to investigate the functionality of human MDSCs. PZH manipulated gut microbiota and metabolites toward a more favorable profile, improved gut barrier function, and suppressed oncogenic and pro-inflammatory pathways, thereby suppressing colorectal carcinogenesis.
- | LY294002 / Eli Lilly
Journal: Grape Seed Proanthocyanidin Ameliorates LPS-induced Acute Lung Injury By Modulating M2a Macrophage Polarization Via the TREM2/PI3K/Akt Pathway. (Pubmed Central) - Nov 27, 2023
In addition, GSP-enhanced PI3K/Akt activity was prevented by TREM2 siRNA. In conclusion, this study demonstrated that GSP could ameliorate LPS-induced ALI by modulating macrophage polarization from M1 to M2a via the TREM2/PI3K/Akt pathway.
- | 5-fluorouracil / Generic mfg.
Journal: Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer. (Pubmed Central) - Nov 24, 2023
In conclusion, this study demonstrated that GSP could ameliorate LPS-induced ALI by modulating macrophage polarization from M1 to M2a via the TREM2/PI3K/Akt pathway. Silencing of the PI3K/Akt/mTOR signaling pathway suppressed the 5-FU resistance of GC cells.
- | Journal: Methionine Promotes Milk Protein Synthesis via the PI3K-mTOR Signaling Pathway in Human Mammary Epithelial Cells. (Pubmed Central) - Nov 24, 2023
In addition, PI3K inhibition assays confirmed that methionine upregulated the expression of both mTOR and p-mTOR through activation of PI3K. Taken together, these findings suggest that methionine positively regulates milk protein synthesis in MCF-10A cells through the PI3K-mTOR signaling pathway.
- | Journal: Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents. (Pubmed Central) - Nov 22, 2023
Cancers with wild-type BRCA, homologous recombination proficiency, or de novo or acquired resistance to PARP inhibition represent a growing population of patients who may benefit from combinatorial PARP inhibitor strategies. We review targeted inhibitors of angiogenesis, epigenetic regulators, and PI3K, MAPK, and other cellular signaling pathways as inducers of homologous recombination deficiency, providing support for the use of PARP inhibitors in contexts not previously considered susceptible to PARP inhibition.
- | LY294002 / Eli Lilly
Journal: Nodakenin alleviates ovariectomy-induced osteoporosis by modulating osteoblastogenesis and osteoclastogenesis. (Pubmed Central) - Nov 22, 2023
In contrast, LY294002, an inhibitor of PI3K, reversed these changes and inhibited the osteogenic differentiation-enabling effect of NK...In addition, oral administration of NK to mice significantly elevated bone mass and ameliorated ovariectomized (OVX)-mediated bone microarchitectural disorders. In conclusion, these data suggest that NK attenuates OVX-induced bone loss by enhancing osteogenesis and inhibiting osteoclastogenesis.
- | trichostatin A (VTR-297) / Vanda
Preclinical, Journal: Quantitative Proteomics Characterization of the Effect and Mechanism of Trichostatin A on the Hippocampus of Type II Diabetic Mice. (Pubmed Central) - Nov 22, 2023
In conclusion, our study revealed that CAT and PRKAA2 were the key proteins involved in the improvement of DE after TSA treatment. ISOX, apicidin, and panobinostat were promising similar drugs and that GSK-1059615, alisertib, and avrainvillamide-analog-6 were promising ancillary drugs to TSA in the treatment of DE.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial suspension, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=106, Suspended, Sponsor: National Cancer Institute (NCI)
ISOX, apicidin, and panobinostat were promising similar drugs and that GSK-1059615, alisertib, and avrainvillamide-analog-6 were promising ancillary drugs to TSA in the treatment of DE. Recruiting --> Suspended
- | Journal: Salidroside suppresses proliferation and migration in prostate cancer via the PI3K/AKT pathway. (Pubmed Central) - Nov 21, 2023
Recruiting --> Suspended Our study demonstrated that in PCa cells, salidroside inhibites proliferation and migration and promots apoptosis via inhibiting PI3K/AKT pathway.
- | LY294002 / Eli Lilly
Journal: Hyperoside Prevents A?42-Induced Neurotoxicity in PC12 Cells and Caenorhabditis elegans. (Pubmed Central) - Nov 21, 2023
The results of molecular docking further indicated that the PI3K/Akt pathways may be involved in the protection of A?42-induced PC12 cells by hyperoside treatment. The study provides theoretical information for research and development of hyperoside as an antioxidant dietary supplement.
- | LY294002 / Eli Lilly
Journal: Salvianolic acid B and tanshinone IIA synergistically improve early diabetic nephropathy through regulating PI3K/Akt/NF-?B signaling pathway. (Pubmed Central) - Nov 21, 2023
The study provides theoretical information for research and development of hyperoside as an antioxidant dietary supplement. Salvianolic acid B and tanshinone IIA can synergistically improve glucose and lipid disorders, liver and kidney damage, and resist kidney inflammation in early DN rats, and the mechanism may be related to regulating PI3K/Akt/NF-?B signaling pathway.
- | Journal, PD(L)-1 Biomarker, IO biomarker: The role and mechanisms of PD-L1 in immune evasion during Talaromyces marneffei infection. (Pubmed Central) - Nov 21, 2023
Treatment with a PD-L1 inhibitor significantly reduced fungal burden, while activating T cell activity and proliferation, thereby promoting fungal clearance. Furthermore, the PI3K signaling pathway may be involved in the regulation of PD-L1 by T. marneffei.
- | Journal: TPN10475 alleviates concanavalin A-induced autoimmune hepatitis by limiting T cell development and function through inhibition of PI3K-AKT pathway. (Pubmed Central) - Nov 20, 2023
in the liver and peripheral immune tissues, and demonstrated that TPN10475 weakened the activation and function of T cells by inhibiting PI3K-AKT signaling pathway. These results suggested that TPN10475 may be a potential drug for the treatment of AIH, and the inhibition of PI3K-AKT signaling pathway may provide new ideas for the study of the pathogenesis of AIH.
- | LY294002 / Eli Lilly
Preclinical, Journal: Trichosanthin-derived peptide Tk-PQ attenuates immune rejection in mouse tracheal allotransplant model by suppressing PI3K-Akt and inducing type II immune polarization. (Pubmed Central) - Nov 20, 2023
Indeed, the immune suppression phenotypes of Tk-PQ was recapitulated by a PI3K inhibitor LY294002. Taken together, Tk-PQ regulates post-transplantation immuno-rejection by modulating the balance of T cell response via the PI3K-Akt pathway, making it a promising peptide based immune rejection suppressant for patients receiving allotransplant.
- || sapanisertib (CB-228) / Calithera
P2 data, Journal, Combination therapy, Metastases: A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer. (Pubmed Central) - Nov 20, 2023
P2
Our findings support inclusion of chemotherapy combinations with investigational agents for advanced or metastatic disease. The primary endpoint was not met and toxicity was manageable.
- | LY294002 / Eli Lilly
Journal: Pectolinarigenin attenuates hepatic ischemia/reperfusion injury via activation of the PI3K/AKT/Nrf2 signaling pathway. (Pubmed Central) - Nov 20, 2023
Further studies found that LY294002 (PI3K inhibitor) suppressed the protective effect of Pec on hepatic I/R injury. In summary, our results show that Pec inhibits oxidative stress, inflammatory responses, and apoptosis, thereby attenuating I/R-induced liver injury and H/R-induced cell damage via activation of the PI3K/AKT/Nrf2 pathway.
- | Journal, IO biomarker: Regulation of Cathelicidin Antimicrobial Peptide (CAMP) Gene Expression by TNF? and cfDNA in Adipocytes. (Pubmed Central) - Nov 18, 2023
These findings suggest a regulatory role of inflammatory mediators, such as TNF? and cfDNA, in adipocytic CAMP expression as a novel putative molecular mechanism in adipose tissue innate immunity.
- | Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm, Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Combination therapy: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 18, 2023
P2, N=12, Active, not recruiting, Sponsor: City of Hope Medical Center
and cfDNA, in adipocytic CAMP expression as a novel putative molecular mechanism in adipose tissue innate immunity. Trial completion date: Sep 2023 --> Sep 2025
- | Preclinical, Journal: Beneficial effect of GABA-rich fermented milk whey on nervous system and intestinal microenvironment of aging mice induced by D-galactose. (Pubmed Central) - Nov 18, 2023
The ameliorative effect of FDH-GABA on premature aging showed a clear dose-response relationship, and at the same time, the changes of intestinal microorganisms showed a certain correlation with the relevant indexes of nervous system. These findings provide insight into the effect of the FDH-GABA intervention on aging, providing a novel means for alleviating detrimental neurodegenerative changes in the aging population.
- || parsaclisib (INCB50465) / Incyte
Trial completion: Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) (clinicaltrials.gov) - Nov 18, 2023
P2, N=42, Completed, Sponsor: Incyte Biosciences Japan GK
These findings provide insight into the effect of the FDH-GABA intervention on aging, providing a novel means for alleviating detrimental neurodegenerative changes in the aging population. Active, not recruiting --> Completed
- | Inlyta (axitinib) / Pfizer, LY294002 / Eli Lilly
Journal: Study on the Protective Effect of Platelet-Rich Plasma Combined with Injection of Pain Points Around Knee Joint on Knee Osteoarthritis and its Molecular Mechanism. (Pubmed Central) - Nov 17, 2023
The effect of the LY294002 +PRP group was better than that of the above groups...PRP can promote chondrocytes proliferation and repair by activating the PI3K/AKT signaling pathway, thereby exerting anti-OA effects. It provides new targets and methods for the clinical treatment of OA.
- | Preclinical, Journal, Immunomodulating: IWP-2 modulates the immunomodulatory properties of human dental pulp stem cells in (Pubmed Central) - Nov 17, 2023
Moreover, hDPSCs exerted the immunosuppressive property after IWP-2 treatment. These results suggest the role of Wnt in inflammatory responses and immunomodulation in dental pulp tissues.
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Journal: Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer. (Pubmed Central) - Nov 16, 2023
These results suggest the role of Wnt in inflammatory responses and immunomodulation in dental pulp tissues. Our findings suggested that the rs10889677 variant as a critical initiator of the PI3K signaling pathway, and buparlisib had the ability to prevent PI3K-non-AKT activation in the pathophysiology of CAC.
- | cisplatin / Generic mfg.
Journal: Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K/AKT/mTOR and MAPK signaling. (Pubmed Central) - Nov 16, 2023
Our findings suggested that the rs10889677 variant as a critical initiator of the PI3K signaling pathway, and buparlisib had the ability to prevent PI3K-non-AKT activation in the pathophysiology of CAC. Deltonin can boost the chemosensitivity of GC cells to cisplatin via inactivating p38-MAPK and PI3K/AKT/mTOR signaling.
- | LY294002 / Eli Lilly
Journal: Role of senkyunolide I in the promotion of neural stem/progenitor cell proliferation via the Akt/?-catenin pathway. (Pubmed Central) - Nov 15, 2023
downregulated differentiated processes. Thus, SEI promoted the NS/PC proliferation and suppressed NS/PC differentiation into neurons and/or astrocytes, therefore SEI could be an interesting and promising candidate for stimulating NSCs.
- | LY294002 / Eli Lilly
Journal: Quercetin improves cerebral ischemia/reperfusion injury by promoting microglia/macrophages M2 polarization via regulating PI3K/Akt/NF-?B signaling pathway. (Pubmed Central) - Nov 15, 2023
Collectively, our findings demonstrate that quercetin facilitates microglia/macrophages M2 polarization by modulating the PI3K/Akt/NF-?B signaling pathway in the treatment of CI/RI. These findings provide novel insights into the therapeutic mechanisms of quercetin in ischemic stroke.
- | doxorubicin hydrochloride / Generic mfg.
Journal: The Therapeutic Mechanisms of Shenyan Oral Liquid I Against Chronic Kidney Disease Based on Network Pharmacology and Experimental Validation. (Pubmed Central) - Nov 14, 2023
These findings provide novel insights into the therapeutic mechanisms of quercetin in ischemic stroke. SOLI exerted a renoprotective effect by regulating the Nephrin-PI3K/AKT autophagy signaling pathway, and these findings provide new ideas for the development of SOLI-based therapeutic approaches for CKD.
- || Review, Journal: PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities. (Pubmed Central) - Nov 14, 2023
Recently, new inhibitors of PI3K/Akt/mTOR signaling have been developed and tested both in preclinical and clinical models. In this review, we outline the role of the PI3K/Akt/mTOR signaling pathway in blood malignancies' cells and gather information on the inhibitors of this pathway that might provide a novel therapeutic opportunity against leukemia.
- || Xalkori (crizotinib) / Pfizer, Votrient (pazopanib) / Novartis, BeiGene
Review, Journal: Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature. (Pubmed Central) - Nov 14, 2023
Dasatinib and megestrol were ineffective in two other different patients. Pazopanib has been demonstrated to be active in advanced GCTs and may be considered as a preferable treatment option.
- | Journal: The miR-210 Primed Endothelial Progenitor Cell Exosomes Alleviate Acute Ischemic Brain Injury. (Pubmed Central) - Nov 14, 2023
Pazopanib has been demonstrated to be active in advanced GCTs and may be considered as a preferable treatment option. These findings suggest that miR210-EPC-EXs protect the brain from acute ischemia- induced cell apoptosis and oxidative stress partially through the VEGFR2/PI3k and TrkB/PI3k signal pathways.
- | LY294002 / Eli Lilly
Journal: Tongqiao Mingmu formula alleviates retinal ganglion cell autophagy through PI3K/AKT/mTOR pathway. (Pubmed Central) - Nov 14, 2023
However, TQMM formula serum could generate an opposite effect and upregulate the expressions of the PI3K/AKT/mTOR pathway genes and proteins. In conclusion, the TQMM formula can prevent glutamate-induced autophagy in RGCs, possibly by activating the PI3K/AKT/mTOR pathway and reducing the expression of autophagy-related biomarkers LC3 and Belicin-1 to attenuate autophagy and maintain RGC viability.